Bengaluru, September 23, 2024: HCG Cancer Centre Bengaluru proudly announces the introduction of the CyberKnife S7 System, an AI-driven, fully automated treatment delivery system featuring real-time motion adaptation. This innovative technology marks a major advancement in treating both cancerous and non-cancerous tumors. The launch event was attended by Dr. B. S. Ajaikumar, Executive Chairman of Healthcare Global Enterprises Limited, and Raj Gore, CEO of Healthcare Global Enterprises Ltd. This state-of-the-art system aims to transform patient care by offering enhanced precision and improved treatment outcomes.
HCG has been a leader in CyberKnife technology in India since 2009, treating over 7,500 patients in the past 15 years. The CyberKnife S7 provides a non-invasive option for tumors located in various areas of the body, including the brain, lung, spine, prostate, and abdomen. It serves as a crucial alternative for patients with inoperable or complex tumors and offers renewed hope for those facing recurrent or metastatic lesions.
Dr. B. S. Ajaikumar emphasized HCG’s leadership in advanced cancer treatments, stating, “We were among the first in India to utilize CyberKnife technology, having successfully treated approximately 5,635 patients in Bengaluru and over 7,500 across our network in the last 15 years. The launch of the CyberKnife S7 underscores our dedication to providing precise, non-invasive therapies targeting both cancerous and non-cancerous tumors. This innovation embodies our commitment to leading in cancer care, ensuring that patients receive the most advanced treatments for optimal outcomes right from the start.”
He added, “This new technology represents a significant shift in our treatment strategy, enhancing our capabilities and aligning with HCG’s vision of delivering outcome-focused, first-time-right treatments that prioritize patient well-being. Our extensive experience, combined with the CyberKnife S7, strengthens our commitment to remaining at the forefront of cancer care, offering innovative and effective therapies.”
Raj Gore, CEO of Healthcare Global Enterprises Ltd, remarked, “With over 15 years of expertise in CyberKnife treatment, the launch of the CyberKnife S7 System is a major milestone for HCG. This system provides exceptional precision and accuracy, enabling higher doses and fewer treatment sessions without sacrificing delivery speed, efficiency, patient comfort, or clinical results. This cutting-edge technology not only enhances our competitive edge but also aligns with our strategic goal of improving patient outcomes and expanding our treatment capabilities.”
Ms. Manisha Kumar, Regional Chief Operating Officer for Karnataka at Healthcare Global Enterprises Limited, stated, “We are excited to bring this advanced technology to HCG Cancer Centre, Bengaluru. The CyberKnife S7 System revolutionizes radiation therapy with its remarkable speed, accuracy, and real-time target tracking. Unlike previous versions, the S7 allows us to address a wider range of conditions, from benign brain tumors to inoperable cancers in the lungs, pancreas, and liver. This upgrade will not only enhance patient care but also solidify HCG’s position as a leading center for cancer treatment.”
With the launch of the CyberKnife S7, HCG Cancer Centre continues to elevate its capabilities, ensuring improved clinical outcomes and a patient-centric approach to care.